Targeted Strategies for Today's Evolving Markets

MissionIR Blog

DelMar Pharmaceuticals, Inc. (DMPI) Starts Presentation at LD Micro Conference

DelMar Pharmaceuticals, Inc. (OTC: DMPI) is a clinical and commercial stage drug development company with a focus on the treatment of cancer. The company is in the midst of conducting clinical trials in the U.S. with its product candidate, VAL-083, which is designed to serve as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. For more information, visit the company’s website at

The three-day LD Micro Invitational in Bel Air, California, features company presentations from more than 200 select high-potential small-cap companies spanning multiple industries. Institutional and retail investors in attendance also have access to numerous networking opportunities and social events to learn more about these companies. For more information on LD Micro, visit
This entry was posted in LD Micro Conference. Bookmark the permalink.

Comments are closed.